4- ((3- (1,6- dihyro- 6- oxo- 9H- purin- 9- yl)- 1- oxopropyl)amino)benzoic acid

02/01/1994 - "Both AIT-082 and PHY improved memory in young mice and restored memory in mice with mild age-induced memory deficits; however only AID-082 was also effective in subjects with moderate deficits. "
09/27/2002 - "Neotrofin, a reported inducer of CNS neurotrophic factor synthesis and release, with memory-enhancing activity and demonstrated restoration of age-induced memory deficits in animals, was tested in patients with mild to moderate Alzheimer's disease. "
10/01/1997 - "AIT-082, a purine analogue, has been shown to reverse age-induced memory deficits in mice and is a growth factor-mimetic agent. "

09/01/2004 - "At 21 days, either AIT-082 or MPSS administration improved function and morphology similarly (less tissue loss and astrogliosis). "

09/27/2002 - "Brain metabolic effects of Neotrofin in patients with Alzheimer's disease."
06/01/2002 - "AIT-082 is currently being developed as a potential treatment for Alzheimer's disease (AD). "
06/20/2003 - "AIT-082 is currently being developed as a potential treatment for Alzheimer's disease and other neurological disorders. "
02/01/1994 - "AIT-082 was devoid of any effects on performance variables and has not shown any toxic side effects, thus making it an interesting potential treatment for working memory deficits associated with aging, strokes, and Alzheimer's disease."
09/27/2002 - "Neotrofin, a reported inducer of CNS neurotrophic factor synthesis and release, with memory-enhancing activity and demonstrated restoration of age-induced memory deficits in animals, was tested in patients with mild to moderate Alzheimer's disease. "

09/01/2004 - "AIT-082 and methylprednisolone singly, but not in combination, enhance functional and histological improvement after acute spinal cord injury in rats."
10/01/1998 - "In October 1997, further preclinical results were presented, demonstrating that treatment with AIT-082 produced an increase in neurotrophic factors following spinal cord injury in rats. "
09/01/2004 - "Preliminary studies indicate that administration of the synthetic purine 4-[[3-(1,6 dihydro-6-oxo-9-purine-9-yl)-1-oxypropyl] amino] benzoic acid (AIT-082, leteprinim potassium) to rats immediately after acute spinal cord injury (SCI), improves functional outcome. "

11/14/2011 - "The aim of this study is to investigate the neuroprotective and ameliorating effects of neotrofin treatment after hypoxic-ischemic-injury-induced neuronal cell death, apoptosis in a neonatal hypoxic-ischemic brain injury rat model. "
06/27/2012 - "Given our results, neotrofin may be useful in reducing brain injury and possessing clinical relevance for the treatment of white matter injury in newborns."
11/14/2011 - "Effects of neotrofin on neonatal hypoxic ischemic brain injury."
11/14/2011 - "Given our results, neotrofin may be useful in reducing brain injury; it possesses clinical relevance for the treatment of hypoxic-ischemic encephalopathy in the newborn."